Lenampicillin hydrochloride is an orally active prodrug of Ampicillin. Lenampicillin hydrochloride is an effective beta-lactam antibacterial agent that inhibits bacterial penicillin-binding proteins. It is applied in the investigation of suppurative skin and soft tissue infection.

Lenampicillin hydrochloride (LAPC) is identified for its main metabolites in rats and dogs. The main metabolite in peripheral plasma is 2,3-butanediol in rats and dogs, On the other hand, high levels of acetoin are found in portal plasma for an early period after the dosing of LAPC. These results show that the biotransformation of propriety in LAPC to acetoin carried out mainly in intestinal tissues, but acetoin is converted to 2,3-butanediol in the liver[3]. Lenampicillin hydrochloride (p.o.; 0-1000 mg/kg) does not cause death in dogs, and the maximum dose of in this acute toxicity study is recorded because of causing emesis[2].